Predict Response to Chemotherapy?

Ultima Vez Modificado: 8 de septiembre del 2006

Share article


Imprima English

Question

Dear OncoLink "Ask The Experts,"

I was diagnosed with Stage IIIC ovarian cancer in Nov. 2005. I had a hysterectomy and tumor debulking at that time. I have most recently been on IV Taxol and Carboplatin chemotherapy, and have responded best to this combination. What is the best predictable factor that will indicate how one person will respond to a specific chemo regime better than others? In the laparoscopy, Dr. Walker was going to send tissue for chemosensitivity assays, but no tumor or malignancy was present.

Answer

Christina S. Chu, MD, Assistant Professor of the Division of Gynecologic Oncology at the University of Pennsylvania Health System, responds:

Your question about how best to predict a cancer's response to chemotherapy is very important. There are a variety of methods available to test an individual's tumor cells in the lab for response to different chemotherapy drugs. All of these methods require harvest of tumor cells, either in a solid biopsy specimen or in fluid. These tests appear to have a good chance of telling us which drugs are NOT useful. Stated another way, when the lab tests say that the cancer cells in the biopsy specimen were resistant to a certain chemotherapy, there is a good correlation to how the tumor will react in the body when treated with the same drug. Unfortunately, the reverse is not true. It is much more difficult for these tests to tell us what drugs will actually cause the tumor to shrink in the body. In addition, tumors are composed of many different types of cells. Some cells may be sensitive to one chemotherapy and resistant to another, while other cells from the same tumor may have different sensitivities.

Imprima English
News
Using existing guidelines to measure response in lesion helps predict liver cancer outcomes

Mar 17, 2010 - In patients treated with locoregional chemotherapy or radiotherapy for hepatocellular carcinoma, assessment of changes to the largest tumor targeted in the first round of treatment, the "primary index lesion," is a useful biomarker of response to treatment when existing guidelines are applied, according to a study in the March 17 issue of the Journal of the American Medical Association.



I Wish You Knew

Understanding prostate cancer screening

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información